Navigation Links
ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver

on with peg-IFN has been completed. Combination therapy including HCV-796 was found to be generally well tolerated. The observed safety profile supports the evaluation of HCV-796 in studies of longer duration.

-- Adverse events across all dose cohorts were generally mild to moderate in severity and were characteristic of the known side effects of interferons.

-- Adverse events that occurred at a frequency of greater than 15 percent across all dose cohorts of HCV-796 plus peg-IFN and peg-IFN alone included headache, chills, myalgias, fever, pain, arthralgia and rash.

-- There were two reports of serious adverse events: one in the placebo arm (pneumonia), and one in the 1000 mg combination cohort (seizure and rhabdomyolysis in a subject receiving high dose methadone chronically).

-- The rate of discontinuation due to adverse events was low across the study. No patient discontinued due to adverse events in the 100, 250, or 500 mg dose cohorts. In the peg-IFN alone group, one patient discontinued due to hypertension; of those that received 1000 mg HCV-796 plus peg-IFN, three patients discontinued due to either vasovagal syncope after a blood draw, rash, or seizure and rhabdomyolysis (in a subject receiving high dose methadone chronically).

-- No dose-limiting toxicities were identified across the range of study doses.

Genetic Sequencing

NS5B sequencing was performed on 36 subjects (11 on peg-IFN alone; 25 HCV- 796 and peg-IFN). Consistent with data from the Phase 1b study of HCV-796 as monotherapy, the only variant of importance detected in patients receiving HCV-796 was a C316Y variant known to have reduced susceptibility to HCV-796. Baseline sequencing did not find any variation from wild type at this position. The C316Y variant was observed in 7 (28 percent) of patients on HCV- 796 plus peg-IFN, occurring less frequently than previously seen in patients receiving HCV-796 as monotherapy, and was not clearly associated w
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:5/5/2015)... , May 5, 2015  In line with CBME ... to the community with a charity program to create ... autism. CBME China team is coordinating ... and maternity manufacturers, brand owners and distributors. All donated ... July 2015. Proceeds from the sale will be used ...
(Date:5/5/2015)... , May 5, 2015   Temptime Corporation , ... health care industry, announced today that its board of ... to chief executive officer.  Mr. Van den ... since 2011. "Renaat deeply values Temptime,s mission ... job of expanding Temptime,s products and services to organizations ...
(Date:5/5/2015)... Sysmex America, Inc., a global leader ... technology, today announces a partnership with Medicus Middleware, ... Sysmex and its distributor partners to offer a ... and clinics that connect Sysmex,s XP-300 moderately complex ... systems. Physician office-based laboratories (POL) often ...
Breaking Medicine Technology:CBME China Launches Charity Program to Support Children with Autism 2Temptime President Renaat Van den Hooff Promoted to CEO 2Sysmex America, Inc. Partners with Medicus Middleware to Provide Physician Office Labs with Instrument Connectivity Directly to EMR 2Sysmex America, Inc. Partners with Medicus Middleware to Provide Physician Office Labs with Instrument Connectivity Directly to EMR 3
... and Company (NYSE: LLY ) announced results ... genetic mutations and disable specific signaling pathways that can ... – a JAK2 inhibitor and a Hedgehog inhibitor – ... Research (AACR) 102nd Annual Meeting in Orlando, Fla.   ...
... N.C., April 4, 2011 Cardioxyl Pharmaceuticals, Inc. ... from studies of its lead clinical candidate, CXL-1020, ... Annual Scientific Session & Expo in New Orleans, ... demonstrate CXL-1020,s ability to work independently from other ...
Cached Medicine Technology:Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer 2Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer 3Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer 4Cardioxyl Pharmaceuticals Presents Data On Its Clinical Candidate, CXL-1020, at the 60th Annual American College of Cardiology Scientific Session 2Cardioxyl Pharmaceuticals Presents Data On Its Clinical Candidate, CXL-1020, at the 60th Annual American College of Cardiology Scientific Session 3Cardioxyl Pharmaceuticals Presents Data On Its Clinical Candidate, CXL-1020, at the 60th Annual American College of Cardiology Scientific Session 4Cardioxyl Pharmaceuticals Presents Data On Its Clinical Candidate, CXL-1020, at the 60th Annual American College of Cardiology Scientific Session 5
(Date:5/6/2015)... Launch Corporation, LLC. is pleased to announce that ... at 17 Tanguay Avenue. Owned and operated by Rick Arnold ... location in New England. , “We are extremely excited for ... founder, co-owner and CEO of Launch. “They have established great ... seeing them continue to establish that positive growth in the ...
(Date:5/6/2015)... NC (PRWEB) May 06, 2015 LINET ... Award of Charlotte in the small business category. The ... The Mayor’s International Community Award is given on an ... area that exhibit outstanding contributions to philanthropy. Since ... the Mayor have hosted the Mayor’s International Community Awards. ...
(Date:5/6/2015)... May 06, 2015 “ Radiation Island ” ... which takes a look at the latest and coolest applications ... the host of AppWatch and technology expert, conducted the app ... the best graphic games on iOS. , Touted as one ... exceptional. It’s loved by users, which is obvious because of ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 With ProPoint: Hand ... within Final Cut Pro X . With ProPoint: ... 3D space to further more customize each preset all with ... are given up to 90 fully customizable effect presets all ... circles, curved arrows, straight arrows, underlines, and more. , ...
(Date:5/5/2015)... May 06, 2015 The ... original research “ Priority interventions to improve the ... a participatory research of the ACCORD program ” ... “Primary care actors, including clinicians, patients and family ... pain management which included knowledge gap, “work in ...
Breaking Medicine News(10 mins):Health News:Jump Up and Celebrate: Launch Trampoline Park Opens in Nashua, NH 2Health News:LINET Americas Wins The Mayor's International Community Award in Charlotte 2Health News:Top Grossing iPhone Game, Radiation Island, Was Featured on NewsWatch 2Health News:FCPX Plugin Developer Pixel Film Studios release Propoint Hand Drawn 2Health News:Priority interventions in chronic non-cancer pain published by Dove Medical Press 2
... could lead to new diabetes treatments, researchers say , MONDAY, ... involved in both insulin action and insulin resistance has been ... an enzyme called PI 3-kinase plays an important role in ... In tests on cells and genetically modified mice, Joslin Diabetes ...
... ... are to offer Allergan implants as part of their standard breast augmentation package. ... (PRWEB) March 29, 2010 -- ... their ongoing attempt to provide the most comprehensive service to their patients having breast ...
... at the University of Gothenburg, Sweden, has shown in a ... the treatment of lung cancer. The discovery was made when ... transgenic mice. This resulted in inhibition of cell growth, fewer ... is being published in the journal Proceedings of the ...
... March 29, 2010 Elsevier, a world leader in ... announced that its Journal of Evidence-Based Dental Practice ... a special March 2010 issue on restorative dentistry to ... in the U.S. "As the most authoritative ...
... ... of HealthcareSource®, a pioneer in talent management solutions designed for the healthcare industry. ... ... solution provider that offers employment screening and onboarding solutions designed for human resources, ...
... levels can lead to serious health problems, experts say , ... a common health problem around the world, experts say, and ... among poor black and Hispanic children, researchers report. , In ... optimal vitamin D levels, the study found. , "This is ...
Cached Medicine News:Health News:'Jekyll and Hyde' Factor May Control Insulin Function 2Health News:Rubicon Medical To Offer Allergan Implants In Breast Enlargement Surgery 2Health News:Promising strategy for treatment of lung cancer 2Health News:Elsevier's Journal of Evidence-Based Dental Practice celebrates 10th year with special issue 2Health News:TalentWise Integrates Employment Screening with Leading Applicant Tracking Solution for Healthcare Industry TalentWise becomes HealthcareSource Certified Integration Partner For Position Manager Product 2Health News:TalentWise Integrates Employment Screening with Leading Applicant Tracking Solution for Healthcare Industry TalentWise becomes HealthcareSource Certified Integration Partner For Position Manager Product 3Health News:Minority Kids Lack Enough Vitamin D 2Health News:Minority Kids Lack Enough Vitamin D 3
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... braces provide pain relief, stabilization and comfort ... patient outcomes. ,The Aspen® "Low Profile" LSO ... When firmly tightened, using the LeverLatch mechanism, ... significant degree of functional mobility and, in ...
... Gunslinger™ Shoulder Orthosis Until now, laborious custom ... of splint. Adjustability was limited and modifications ... best, difficult and cumbersome.,The GunSlinger evolved from ... a major Boston teaching hospital. This orthosis ...
Medicine Products: